Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated According to UGT1A1 Genotyping Versus Regorafenib Monotherapy in Patients With Previously Treated Metastatic Colorectal Cancer: A Prospective, Randomized, Controlled Study

NCT03880877 is registered in ClinicalTrials.gov with Kaohsiung Medical University Chung-Ho Memorial Hospital as lead sponsor.

NCT NCT03880877
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03880877 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated According to UGT1A1 Genotyping Versus Regorafenib Monotherapy in Patients With Previously Treated Metastatic Colorectal Cancer: A Prospective, Randomized, Controlled Study
Lead sponsor
Kaohsiung Medical University Chung-Ho Memorial Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
February 26, 2019
Completion date
December 31, 2021
Enrollment
153 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer